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Systematic Review
Efficacy and Safety of Methylprednisolone
Sodium Succinate in Acute Spinal Cord
Injury: A Systematic Review
Michael G. Fehlings, MD, PhD, FRCSC, FACS1,2, Jefferson R. Wilson, MD, PhD2,3,
James S. Harrop, MD4, Brian K. Kwon, MD, PhD5, Lindsay A. Tetreault, PhD1,6,
PaulM. Arnold,MD7, JeffreyM. Singh,MD, FRCPC1, GregoryHawryluk, MD, PhD8,
and Joseph R. Dettori, PhD, MPH9
Abstract
Study Design: Systematic review and meta-analysis.
Objective: The objective of this study was to conduct a systematic review to assess the comparative effectiveness and safety of
high-dose methylprednisolone sodium succinate (MPSS) versus no pharmacological treatment in patients with traumatic spinal
cord injury (SCI).
Methods: A systematic search was performed in PubMed and the Cochrane Collaboration Library for literature published between
January 1956 and June17, 2015. Included studieswere critically appraised, andGrades of RecommendationAssessment,Development
and Evaluationmethodswere used to determine the overall quality of evidence for primary outcomes. Previous systematic reviews on
this topic were collated and evaluated using the Assessment of Multiple Systematic Reviews scoring system.
Results: The search yielded 723 citations, 13 of which satisfied inclusion criteria. Among these, 6 were primary research articles
and 7 were previous systematic reviews. Based on the included research articles, there was moderate evidence that the 24-hour
NASCIS II (National Acute Spinal Cord Injury Studies) MPSS regimen has no impact on long-term neurological recovery when all
postinjury time points are considered. However, there is also moderate evidence that subjects receiving the same MPSS regimen
within 8 hours of injury achieve an additional 3.2 points (95% confidence interval ¼ 0.10 to 6.33; P ¼ .04) of motor recovery
compared with patients receiving placebo or no treatment.
Conclusion: Although safe to administer, a 24-hour NASCIS II MPSS regimen, when all postinjury time points are considered, has
no impact on indices of long-term neurological recovery. When commenced within 8 hours of injury, however, a high-dose
24-hour regimen of MPSS confers a small positive benefit on long-term motor recovery and should be considered a treatment
option for patients with SCI.
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Introduction
Given its potent anti-inflammatory actions, methylpredniso-
lone sodium succinate (MPSS) has a long history of use across
a wide spectrum of disease. Within the context of traumatic
spinal cord injury (SCI), preclinical animal studies have
demonstrated mixed results with regard to the neuroprotective
efficacy of MPSS.1-4 From the standpoint of clinical investiga-
tion, randomized trials, namely, the National Acute Spinal
Cord Injury Studies (NASCIS), investigating the potential effi-
cacy and safety of MPSS, have formed the basis for the largest
therapeutic studies completed in the history of SCI research.
Although interpretation of, and reaction to, the results of these
studies have varied over time, their publication led to the wide-
spread adoption of this therapy by clinicians throughout the
world. As evidence of this, in a 2006 survey study polling the
membership of the North American Spine Society, 86% of
respondents indicated that they would choose to administer
MPSS to SCI patients as per the recommendations of the NAS-
CIS II and III studies; however, concern surrounding medico-
legal reprisal for not administering MPSS was listed as the
major factor motivating decision making in a large faction of
these respondents.5
In spite of the extensive use of MPSS for SCI over the
past several decades, the appropriateness of this treatment
approach remains a contentious topic.6,7 Opponents of the
routine use of MPSS for acute SCI have highlighted con-
cerns regarding the conduct of the NASCIS trials and the
reported results. These include the reliance on subgroup
analysis (particularly based on timing of MPSS initiation),
the small reported effect size for neurologic improvement,
and the potential for harmful and serious adverse events.8 In
order to quell the existing controversy, a number of attempts
have been made by several different groups to review the
existing evidence, with the aim of providing clinicians with
specific evidence-based recommendations related to this
treatment.9,10 In spite of such attempts, debate within the
clinical community continues, leaving the physician caring
for acute SCI patients in a precarious position where admin-
istering or not administering MPSS can be questioned and
challenged.
Based on this background, the purpose of this systematic
review was to address the following key questions (KQ): In
adult patients with acute complete or incomplete traumatic
SCI: (1) What is the efficacy and effectiveness of MPSS com-
pared with no pharmacologic treatment? (2) What is the safety
profile of MPSS compared with no pharmacologic treatment?
(3) What is the evidence that MPSS has differential efficacy or
safety in subpopulations?
Materials and Methods
Electronic Literature Search
We conducted a systematic search in PubMed and the
Cochrane Collaboration Library for literature published
between January 1956 and June 17, 2015, on patients with
acute traumatic SCI treated with MPSS. The search was
limited to human studies published in or translated to the
English language. Reference lists of key articles were also
systematically checked to identify additional eligible arti-
cles. We included studies that evaluated the efficacy and
safety of MPSS compared with no treatment or placebo in
patients 13 years with acute SCI (Table 1). With respect
to study design, all randomized controlled trials were
included. Severity of injury in SCI patients is a well-
known factor that is associated with outcome.11-14 Severity
of SCI may also influence the clinical decision of whether
to administer MPSS. Therefore, we included observational
studies that controlled for SCI severity, as measured by
baseline motor status and/or complete versus incomplete
injury. We excluded studies on patients with penetrating
injuries to the spinal cord; cord compression due to tumor,
hematoma, or degenerative disease; and no neurological
deficit following trauma. Furthermore, we excluded animal
studies, nonclinical studies, studies with a follow-up rate of
<50%, small studies with n<10 per treatment group, and
studies reporting nonclinical outcomes of efficacy or safety.
Two investigators (JRD, JRW) reviewed the full texts of
potential articles to obtain a final collection of relevant
studies.
Data Extraction
From the included articles, the following data was extracted:
study design, patient demographics, treatment details, study
inclusion/exclusion criteria, injury severity, follow-up dura-
tion, rates of follow-up for each treatment group, and out-
comes assessed. We attempted to identify studies with
overlapping data and only reported the data from the most
complete study (largest sample size) in order to prevent
double counting.
Risk of Bias and Overall Strength of Body of Literature
Risk of bias was assessed by combining epidemiologic
principles with characteristics of study design. Risk of bias
was determined for each article using criteria set by The
Journal of Bone and Joint Surgery15 for therapeutic studies
and modified to delineate criteria associated with metho-
dological quality and risk of bias based on recommenda-
tions made by the Agency for Healthcare Research and
Quality16,17 (see Supplemental Digital Material for risk
of bias evaluation).
After individual article evaluation, the strength of the over-
all body of evidence with respect to each primary outcome was
determined based on precepts outlined by the Grades of Rec-
ommendation Assessment, Development and Evaluation
(GRADE) Working Group.18,19
The initial strength of the overall body of evidence was
considered “High” if the majority of the studies were ran-
domized controlled trials and “Low” if the majority of the
studies were observational studies. Criteria for downgrading
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published evidence 1 or 2 levels included (1) serious risk of
bias, (2) inconsistency of results, (3) indirectness of evi-
dence, (4) imprecision of the effect estimates (eg, wide
confidence intervals), or (5) non–a priori statement of sub-
group analyses. Alternatively, the body of evidence could be
upgraded 1 or 2 levels based on the following factors: (1)
large magnitude of effect or (2) dose-response gradient. The
final overall strength of the body of literature expresses our
confidence that the effect size lies close to the true effect
and the extent to which it is believed to be stable based on
the adequacy of or the deficiencies in the body of evidence.
An overall strength of “High” means that we are very con-
fident that the true effect lies close to that of the estimated
effect. A “Moderate” rating means that we are moderately
confident in the effect estimate; the true effect is likely to
be close to the estimated effect, but there is a possibility
that it is substantially different. An overall strength of
“Low” means that our confidence in the effect estimate is
limited; the true effect may be substantially different from
the estimate. Finally, a rating of “Very Low” means that we
have very little confidence in the effect estimate; the true
effect is likely to be substantially different than the esti-
mated effect. In addition, this rating may be used if there
is no evidence or it is not possible to estimate an effect.
Data Analysis
Results were pooled when 2 or more studies presented the
same outcomes at similar time periods. We considered
the risk of bias when deciding whether to pool data between
the prospective cohort studies and randomized controlled
trials. Specifically, we pooled data from prospective cohort
studies if they had a low risk of bias and controlled for
potential confounding factors. For effectiveness outcomes,
pooled data was stratified by study design to demonstrate
the effect of adding nonrandomized results. To compare the
estimates of procedure effectiveness across studies using
continuous outcomes, weighted mean differences were com-
puted with 95% confidence intervals (CIs). For safety out-
comes, we calculated the risk difference (RD) and 95% CIs.
Table 1. Inclusion and Exclusion Criteria.
Study
Component Inclusion Exclusion
Participants  Adults with traumatic acute spinal cord injury (complete or incomplete)  Pediatric patients <13 years old
 Pregnancy
 Penetrating injuries to spinal cord
 Cord compression due to tumor, hematoma
or degenerative disease (eg, CSM)
 Patients without neurological deficit
following trauma
Intervention  MPSS
Comparators  Placebo
 Standard care without pharmacologic intervention
Outcomes Efficacy/effectiveness
 Change in motor scores
 Change in sensation (light touch, pinprick)
Safety
 Complications, adverse events
 Death
 Nonclinical outcomes
Study design  KQs 1, 2, 3: Comparative studies (RCTs and observational studies with
concurrent controls)
 Follow-up rate of at least 50%
 n  10 per group
 Observational comparative studies must control for severity of spinal
cord injury as evaluated by motor status at baseline and/or complete or
incomplete injury
 KQ 3: Subgroup analyses from comparative studies
 Animal studies
 Nonclinical studies
 Follow-up rate of at <50%
 n < 10 per group
 No control for injury severity
Publication  Studies published or translated into English in peer reviewed journals  Abstracts, editorials, letters
 Duplicate publications of the same study that
do not report on different outcomes
 Single reports from multicenter trials
 White papers
 Narrative reviews
 Articles identified as preliminary reports
when results are published in later versions
Abbreviations: CSM, cervical spondylotic myelopathy; MPSS, methylprednisolone sodium succinate; KQ, key question; RCT, randomized controlled trial.
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We assumed a random-effect model using the Mantel-
Haenszel method. Calculations and plots for effectiveness
outcomes were implemented in RevMan,20 while the com-
plications plot was made with R (version 3.2.1).21
To explore the possibility of differential effectiveness,
we compared outcomes within subgroup stratum when
data was available. We tested the difference between
subgroups by calculating the I2 statistics. We displayed
the estimates visually with Forest plots to demonstrate
the differential effect. When the stratum-specific effect
measures and their CIs fall on opposite sides of the over-
all effect, this represents a differential effect.
Results
Study Selection
Our electronic and bibliography search yielded 723 cita-
tions. Of these, we excluded 693 based on information
available in the title or abstract. The full texts of 30 articles
were obtained and further investigated. After full text
review, we excluded 17 studies for the following reasons:
no control for baseline severity (n ¼ 13), no outcome of
interest (n ¼ 1), dexamethasone was evaluated instead of
MPSS (n ¼ 1), penetrating wounds (n ¼ 1), and population
size <10 (n ¼ 1). A list of excluded articles can be obtained
in the Supplemental Material.
Among the remaining 13 studies, 7 were systematic
reviews published between 2000 and 2014. The systematic
reviews differed with respect to inclusion criteria, metho-
dology, and conclusions (Table 2). The quality of the sys-
tematic reviews ranged from 2/11 (low quality) to 9/11
(high quality) as assessed by the Assessment of Multiple
Systematic Reviews (AMSTAR) evaluation tool (see Sup-
plemental Material for details). All included the NASCIS II
study. Of the remaining 6 studies that met our inclusion
criteria, four were randomized controlled trials and 2 were
prospective cohort studies (Figure 1).
Characteristics of Included Studies (Table 3)
Three randomized controlled trials (4 publications)22-25 and
1 prospective cohort study26 evaluated the efficacy and
safety of MPSS, while 3 additional studies (2 randomized
controlled trials and 1 prospective cohort study) provided
further evidence on its safety.27-29 In 1990 and 1992,
Bracken et al published a double-blind randomized con-
trolled trial, also known as NASCIS II, with 6 weeks,
6 months, and 1 year of follow-up. They randomized 487
patients across 3 treatment arms: (1) MPSS bolus dose of
30 mg/kg at hospital admission, followed by an infusion at
5.4 mg/kg/h for the following 23 hours; (2) naloxone; or
(3) placebo. Naloxone and its placebo were provided in
100-ampule sets of 2-mL parabens-free ampules and pre-
pared at a concentration of 25.0mg/mL. This was followed
by a third and final NASCIS study that compared 24-hour
versus 48-hour MPSS infusion using the same dose as
NASCIS II, as well as to a 48-hour infusion of the
putative neuroprotective drug Tirilazad. All patients were
randomized to receive treatment within 8 hours of injury,
with the analysis stratified according to whether
treatment was initiated before or after 3 hours of injury
(Table 4).29
Otani et al24 published an article in Japanese that rando-
mized 117 patients to a MPSS group (n ¼ 70) or a standard
care group (n ¼ 47). Treatment with other drugs, concomitant
procedures (such as decompression of the spinal cord or reduc-
tion of a dislocation or a fracture), and rehabilitation were
performed at the discretion of the attending physician. Neither
the patients nor the outcome assessors were blinded to the
treatment. Seventy-four percent of patients attended the
6-month follow-up visit.
Matsumoto et al27 compared the incidence of complications
during the first 2 months after injury in 46 patients with cervi-
cal SCI. Patients were randomized to receive MPSS using the
NASCIS II protocol or a placebo, though the methods of ran-
dom generation and concealment were not clear. All patients
received treatment within 8 hours. At baseline, the MPSS group
presented with more severe injuries: 39% in the MPSS group
versus 26% in the placebo group with Frankel grade A, and 4%
in the MPSS group versus 30% in the placebo group with
Frankel grade D.
Wilson et al28 assessed inpatient complications after trau-
matic cervical SCI from the Surgical Timing in Acute Spinal
Cord Injury Study data registry. Patient information was col-
lected on adults with cervical SCIs who were enrolled at
6 North American centers over a 7-year period. This study
included patients who underwent a standardized American
Spinal Injury Association neurological examination within
24 hours of injury and had follow-up information at the index
hospital discharge. Decisions surrounding the administration
of MPSS were made at the discretion of the spinal surgeon and
the treating team.
Evaniew et al performed a prospective multicenter study
using the Rick Hansen Spinal Cord Injury Registry to eval-
uate the impact of MPSS on motor recovery at the end of
inpatient rehabilitation or discharge to the community from
acute care.26 Forty-four patients received MPSS within 8
hours of acute injury following the NASCIS II regiment.
Patients treated with an additional 24 hours of MPSS were
also included. The control group consisted of 44 subjects
who did not receive MPSS and was selected using propen-
sity score matching. Despite this matching, those who
received MPSS had a longer time from injury to first
assessment of motor scores (median 72 vs 56 hours).
Motor function scores (upper extremity, lower extremity,
and total) were determined using the International Stan-
dards for Neurologic Classification of Spinal Cord Injury.
Safety was determined by collecting rates of in-hospital
mortality, urinary tract infections, pneumonia, ulcers, deep
vein thrombosis or pulmonary embolism, surgical site
infections, and sepsis using International Classification of
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What Is the Efficacy of Methylprednisolone Sodium
Succinate Compared With No Pharmacologic
Treatment?
Three randomized trials22-25 and 1 prospective observational
study evaluated the efficacy of MPSS compared with no phar-
macologic treatment.26 Based on the randomized controlled
trials, there was no effect of MPSS on motor function at
6 weeks, 6 months, or 12 months (Figure 2). Likewise, in the
observational study, there was no difference between those
who did and did not receive MPSS in terms of total motor
recovery (13.7 vs 14.1, respectively; P ¼ .43), upper extremity
motor recovery (7.3 vs 6.4; P ¼ .38), or lower extremity motor
recovery (6.5 vs 7.7; P ¼ .40). Pinprick sensation was signif-
icantly improved at 6 months in one randomized controlled
trial (mean difference ¼ 3.37; 95% CI ¼ 0.75 to 5.99)23 but
not in 2 other trials at 12 months (Figure 3).23,25 Similar results
were seen for light touch (Figure 4).
What Is the Safety Profile of MPSS Compared With No
Pharmacologic Treatment?
There was no statistical difference between groups in the
pooled risk of death, wound infection, gastrointestinal hemor-
rhage, sepsis, pulmonary embolism, urinary tract infection,
pneumonia, or decubiti. One prospective nonrandomized study
evaluated the risk of one or more complications and found a
lower risk in those receiving MPSS, after controlling for sever-
ity of injury and other baseline differences (risk difference ¼
12.6%, 95% CI¼ 3.1% to 22.1%; Figure 5). In one randomized
controlled trial comparing 24-hour versus 48-hour infusion of
MPSS, there was a significantly higher incidence of severe
pneumonia (P ¼ .02) in the 48-hour group. Additionally, there
was an increased incidence of severe sepsis in the 48-hour
group, though the difference between the 24-hour and
48-hour groups for this outcome was within the limits of
chance (P ¼ .07).29
What Is the Evidence That MPSS Has Differential
Efficacy or Safety in Subpopulations?
In the study by Bracken et al, there was a differential effect of
MPSS on motor recovery compared with controls depending on
the timing of MPSS administration. Patients receiving MPSS
within 8 hours had a mean 4.8- and 5.2-point improvement in
motor scores at 6 and 12 months follow-up compared with a
mean 3.9- and 5.8-point deterioration when administered after
8 hours (Figure 6). There was no evidence of a differential
effect of the timing of MPSS administration on pinprick or
light touch (Figures 7 and 8).
Two additional randomized controlled trials and one
prospective observational study compared MPSS to a con-
trol in patients receiving treatment within 8 hours. Based
on the randomized controlled trials, pooled results at final
follow-up (6 or 12 months) demonstrated a modest
improvement of 3.88 (95% CI ¼ 0.50 to 7.27; P ¼ .02)
in mean motor scores in the MPSS group compared with
the control group. When adding the results of the prospec-
tive cohort study (median follow-up of 127 and 117 days
in the MPSS and control groups, respectively), this mean
difference decreased to 3.21 (95% CI ¼ 0.10 to 6.33; P ¼
.04; Figure 9).
Evidence Summary (Table 5)
There is moderate evidence that MPSS (compared with no
treatment or placebo) administered according to the dose
and duration of the NASCIS II protocol confers no benefit
in motor recovery, pinprick, or light touch when initiated at
indiscriminate time periods following acute SCI. However,
there is moderate evidence of a small benefit in motor
recovery when MPSS is administered within 8 hours of
injury compared with no treatment. There is no difference
between groups in the pooled risk of death, wound infec-
tion, gastrointestinal hemorrhage, sepsis, pulmonary embo-
lism, urinary tract infection, pneumonia, or decubiti. The
evidence for safety is moderate. There may be a higher
incidence of severe pneumonia and increased incidence of
severe sepsis when the duration of infusion increases from
24 hours to 48 hours.
Discussion
The primary goal of this systematic review was to deter-
mine the efficacy and safety of MPSS compared with no
treatment or placebo. While the majority of primary
research articles emanated from prospective randomized
Figure 1. Literature search.
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controlled trials, 2 observational studies also met eligibil-
ity criteria and were included in this review. With respect
to the overall impact of MPSS, there were no differences
in motor and sensory neurological recovery between
patients treated with MPSS and those receiving placebo
or no treatment. The overall strength of this conclusion
was “Moderate,” meaning that, based on assessment of
risk of bias and the strength of the overall body of
evidence, we are moderately confident that the calculated
effect estimate reflects the true estimate.
From the perspective of safety, when considering the NAS-
CIS II 24-hour MPSS regimen, there was a trend toward
reduced mortality in patients receiving MPSS as compared to
no treatment. Similarly, with respect to complications, there
were no significant differences between patients who
received the 24-hour NASCIS II regimen of MPSS and
Figure 3. Pinprick, all patients.
Figure 2. Motor scores, all patients.
*Prospective cohort study with median follow-up of 127 and 117 days in the MPSS and control groups, respectively.
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those who did not. There were, however, trends toward an
increased incidence of pulmonary embolism and gastroin-
testinal hemorrhage in patients treated with MPSS; the rela-
tive severity of these events and their impact on recovery
and mortality is unknown. In general, when considering the
24-hour NASCIS II MPSS regimen, we can conclude with a
moderate degree of confidence that there are no significant
differences in rates of mortality or other complication
between treated and untreated patients. Although not the
primary focus of this review, compared to patients receiving
the 24-hour NASCIS II regimen, patients treated with the
48-hour NASCIS III regimen experienced higher rates of
severe sepsis (P ¼ .02) and pneumonia (P ¼ .07); this may
represent a valid argument against the administration of the
48-hour regimen to SCI patients (Table 5).
We also evaluated outcomes based on time to drug
administration and specifically examined the impact of
MPSS within the first 8 hours of injury. The importance
of this time window was established based on a subgroup
analysis from the NASCIS II study: the authors reported a
significantly larger improvement in long-term motor score
recovery (an additional 4 points of improvement) in patients
receiving the 24-hour MPSS compared to those receiving
placebo. Critics of the NASCIS II study have commented
on the potential bias associated with this “post hoc” retro-
spective subanalysis. In reality, however, the authors of the
NASCIS II study indicate that an a priori hypothesis was
made that the effects of MPSS are influenced by how
quickly treatment is administered postinjury; that said, the
specific method for selecting the 8-hour cutoff was not fully
described in the primary manuscript text. However, in sub-
sequent articles, rationale for selecting the 8-hour cutoff is
further explained. In a commentary piece published in 2000
by Bracken, he indicates,
It is important that major analytic stratifications be part of the
original proposal and such was the case in NASCIS 2, which
proposed to the National Institutes of Health to analyze “time to
loading dose.” With respect to how data should be categorized, it is
perfectly acceptable to use statistical criteria (mean, median,
mode) to operationalize a hypothesis about early versus late initia-
tion of treatment because the variable distribution is almost always
unknown before the trial is completed. This is particularly so when,
as in the NASCIS trials, there was no a priori biologic rationale for
defining a dichotomy. The whole hour close to the median (8.5
hours) was used because a more precise representation of time was
unwarranted as we only wished to classify “early” versus “late”
treatment. It is certainly an unacceptable analytic practice to ana-
lyze multiple cut-off points while presenting only the most favor-
able one; this was not done in the NASCIS.
These points are further supported by commentary in the
original NASCIS II NIH grant proposal and in more recent
Cochrane meta-analyses.30,31 While it remains unfortunate that
the rationale provided above was not included in the primary
NASCIS II manuscript, this justification should serve to estab-
lish the a priori nature of the “time to effect hypothesis,” and
disabuse individuals of the notion that the 8-hour cutoff was
chosen as a matter of convenience given the presence of a
positive effect.
In summary, when considering all studies included in our
meta-analysis, patients receiving MPSS within 8 hours of
injury had significantly larger motor gains at a minimum of
6 months follow-up, with treated patients experiencing an
additional 3.2 points of motor recovery (95% CI ¼ 0.10 to
6.3). When considering only randomized data, this margin
of benefit increased to an additional 3.8 points of motor
recovery (95% CI ¼ 0.50 to 7.27), with a “Moderate”
degree of confidence in this estimate. Although the magni-
tude of the effect observed is ostensibly small, the clinical
Figure 4. Light touch, all patients.
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significance of such an improvement is unknown and likely
varies from patient to patient depending on the specifics of
the injury, including its severity and neurological level. Of
relevance, in a recent survey study, SCI patients were pre-
sented with an objective summary of the potential risks and
benefits of MPSS based on the trials discussed above.32
Overall, 41 of 69 respondents (59.4%) felt very strongly
that the motor and sensory benefits observed with the NAS-
CIS II MPSS dose administered within 8 hours of injury
would be clinically important. Future work is needed to
improve the interpretability of neurological measures in the
context of SCI and to define what constitutes a clinically
Figure 5. Complications.
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important change. It is, nonetheless, important to acknowl-
edge that the statistically significant improvement in motor
function demonstrated by the most rigorously performed
clinical studies represents fewer than 5 motor points.
Appreciating the small magnitude of this improvement is
important for establishing realistic expectations about the
neuroprotective efficacy of MPSS in acute SCI.
In addition to including individual studies, we also con-
sidered previous systematic reviews in order to gauge how
other groups assessed the evidence on this topic. Across
the 7 systematic reviews that met our inclusion criteria,
conclusions and methodology varied substantially. With
respect to methodological quality, as evaluated by the
AMSTAR score, 3 reviews were rated as low quality,
3 were rated as medium quality, and 1 was rated as high
quality. Of note, the single review deemed to be high
quality (Cochrane meta-analysis authored by Bracken
et al) supported a positive impact of the 24-hour NASCIS
Figure 7. Timing of MPSS administration and pinprick.
Figure 6. Timing of MPSS administration and motor scores.
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II MPSS regimen started within 8 hours of injury on long-
term motor recovery, with overall results very similar to
those observed in this review.
Recently a systematic review and meta-analysis by Eva-
niew et al, published after our inclusion dates, sought to
determine the impact of MPSS on motor recovery and risk
of adverse events.33 This systematic review concluded, in
part, that the pooled evidence does not demonstrate a sig-
nificant long-term benefit for MPSS in patients with acute
SCI. Furthermore, the authors conclude that their findings
support current guidelines against routine use; however,
they also note that strong recommendations are not war-
ranted due to limited confidence in the effect estimate. Our
systematic review differs from theirs in 2 important areas.
First, we pooled studies into a final follow-up group with 6-
or 12-month follow-up, which included 3 studies: Otani et al
(6-month follow-up), Pointillart et al (12-month follow-up),
and Bracken et al (12-month follow-up). This seems reason-
able given the profile of recovery for SCI patients, with the
bulk of improvement occurring in the first 6 to 9 months
postinjury.34 On the other hand, Evaniew et al defined
6-month follow-up as short-term and therefore did not
include Otani et al in the long-term meta-analysis. As a
result, they report a nonsignificant result in long-term motor
improvement. Second, given that severity of injury has the
largest prognostic effect on SCI recovery and may influence
the decision on whether to administer MPSS, we only
included observational studies that controlled for this
Figure 8. Timing of MPSS administration and light touch.
Figure 9. Motor score in patients treated within 8 hours at final follow-up of 6-12 months.
*Evaniew had a median follow-up of 122 days
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potential confounder. Evaniew et al included observational
studies that did not control for severity. Given that patients
with a more severe injury may be more likely to receive
MPSS, the effect of MPSS on prognosis would be under-
estimated in these studies.
Study Limitations
Several limitations of this review must be recognized.
First, many of the included studies had methodological
shortcomings and risk of bias that resulted in the down-
grading of the overall strength of evidence. As a result,
the overall strength of evidence was found to be moderate
for all 3 key questions. Second, although other studies
have evaluated other types of corticosteroids apart from
MPSS, as well as other dosing regimens of MPSS, these
were not included in this review; this decision was based
primarily on a desire to focus on studies comparing MPSS
to no treatment or placebo in order to obtain a better
estimate of the independent effects of this medication.
Last, when evaluating the impact of MPSS on certain sub-
populations of patients, we chose to examine those receiv-
ing treatment within 8 hours of injury. Although this may
be somewhat arbitrary from a biological perspective, it
was chosen given the widespread adoption of this time
window by clinicians throughout the world following the
findings of the NASCIS II subanalysis. As a result, we felt
it necessary to critically evaluate the existing evidence
with respect to this time threshold.
Conclusions
When considering all time points of drug administration, there
is moderate evidence that the 24-hour NASCIS II MPSS
Table 5. Complications From the NASCIS III Trial Comparing 24-Hour Versus 48-Hour Infusion.
6-Week Complications Combined 6- and 12-Month Complications
24-Hour Infusion 48-Hour Infusion 24-Hour Infusion 48-Hour Infusion
Urinary tract infection Mild-moderate 34.4 38.3 53.1 49
Severe 0 0 0.8 3.3
Decubiti Mild-moderate 12.3 13.6 13.8 13.4
Severe 0.6 0.6 3.4 6
Other infection Mild-moderate 3.9 7.8 4.1 4
Severe 0 0 0.7 0.7
Phlebitis Mild-moderate 2.6 1.3 0.7 0
Severe 0 0 0 0
Incision, pin, halo infection Mild-moderate 1.9 2.6 1.4 0.7
Severe 0.6 1.9 0 0
Sepsis Mild-moderate 3.9 4.5 0 1.3
Severe 0.6 2.6 0 1.3
Adult RDS Mild-moderate 1.9 1.9 0 0
Severe 1.3 1.9 0.7 0
Atelectasis Mild-moderate 5.2 7.1 1.4 0.7
Severe 0 0 0.7 0
Other respiratory failure Mild-moderate 7.8 9.1 1.4 0
Severe 1.9 3.2 0 0.7
Pneumonia Mild-moderate 12.3 11 2.8 3.4
Severe 2.6 5.8 1.4 1.4
GI hemorrhage Mild-moderate 0 1.3 0 0
Severe 0 0.6 0 0
Thrombophlebitis Mild-moderate 2.6 4.5 2.1 2.7
Severe 0.6 0 1.4 0.7
Pulmonary embolus Mild-moderate 0 0.6
Severe 1.3 0.6
Bradycardia Mild-moderate 2.6 0.6
Severe 1.3 0
Tachycardia Mild-moderate 0.6 2.6
Severe 0 0
Other arrhythmia Mild-moderate 0.6 1.9
Severe 0 0
Paralytic ileus Mild-moderate 1.3 3.2
Severe 0 0.6
Other complications Mild-moderate 11.7 18.2
Severe 4.5 5.8
Abbreviations: GI, gastrointestinal; RDS, respiratory distress syndrome.
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regimen has no impact on indices of long-term neurological
recovery. However, there is moderate evidence of a small
improvement in motor recovery when the same regimen is
administered within 8 hours of injury. Although there is mod-
erate evidence confirming the safety of the 24-hour regimen,
there may be a higher incidence of infectious complications
when the duration of infusion increases to 48 hours.
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